Literature DB >> 30056431

Suicidal Ideation Assessment in Individuals with Premanifest and Manifest Huntington Disease.

Melissa Wesson1, Nicholas R Boileau2, Joel S Perlmutter3,4, Jane S Paulsen5, Stacey K Barton3, Michael K McCormack6,7, Noelle E Carlozzi2.   

Abstract

BACKGROUND: Huntington disease (HD) is associated with increased risk of suicide.
OBJECTIVE: This study compares suicide ideation in HD to the general population, assesses factors associated with increased prevalence of suicidal thoughts, and compares clinician-rated to self-reported assessments of suicidal ideation.
METHODS: We examined 496 participants with premanifest or manifest HD. Clinician-rated suicidal ideation was measured using the Problem Behaviors Assessment - short form. Self-reported ideation was measured using two items from the HDQLIFE Concern with Death and Dying item bank. Independent sample t-tests were conducted to compare the prevalence of suicidal thoughts between our HD sample and the U.S. POPULATION: Logistic regression analyses were used to determine characteristics associated with higher odds of clinically significant suicidal ideation. Kappa agreement coefficients were calculated to evaluate concurrence between clinician-rated and self-reported assessments.
RESULTS: Our sample had a significantly higher occurrence of suicidal ideation (19.76%) and suicidal plans (2.1%) than the general population (p < 0.0001). Odds of clinically significant suicidal ideation were 6.8 times higher in females (p = 0.04) on the clinician measure, and Hispanic/Latinos had 10.9 times higher odds than non-Hispanics (p = 0.025) on the self-report measure. Clinician-rated assessment had fair agreement (k = 0.2-0.4) with self-reported assessments, except in early stage HD where there was no overlap in the identification of participants with clinically significant suicidal ideation. DISCUSSION: Assessment for suicidal ideation and clinically significant suicidal thoughts in HD with a multimodal approach that includes clinician-rated and self-report measures is critical at all stages of the disease.

Entities:  

Keywords:  Huntington disease; comparing methods; suicidal ideation; suicide; suicide assessment

Mesh:

Year:  2018        PMID: 30056431      PMCID: PMC6108173          DOI: 10.3233/JHD-180299

Source DB:  PubMed          Journal:  J Huntingtons Dis        ISSN: 1879-6397


  46 in total

1.  Huntington disease: clinical care and evaluation.

Authors:  I Shoulson; S Fahn
Journal:  Neurology       Date:  1979-01       Impact factor: 9.910

2.  New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system).

Authors:  N E Carlozzi; N R Downing; M K McCormack; S G Schilling; J S Perlmutter; E A Hahn; J S Lai; S Frank; K A Quaid; J S Paulsen; D Cella; S M Goodnight; J A Miner; M A Nance
Journal:  Qual Life Res       Date:  2016-07-08       Impact factor: 4.147

3.  Critical periods of suicide risk in Huntington's disease.

Authors:  Jane S Paulsen; Karin Ferneyhough Hoth; Carissa Nehl; Laura Stierman
Journal:  Am J Psychiatry       Date:  2005-04       Impact factor: 18.112

4.  Race/ethnicity, substance abuse, and mental illness among suicide victims in 13 US states: 2004 data from the National Violent Death Reporting System.

Authors:  D L Karch; L Barker; T W Strine
Journal:  Inj Prev       Date:  2006-12       Impact factor: 2.399

5.  Disagreement between self-reported and clinician-ascertained suicidal ideation and its correlation with depression and anxiety severity in patients with major depressive disorder or bipolar disorder.

Authors:  Keming Gao; Renrong Wu; Zuowei Wang; Ming Ren; David E Kemp; Philip K Chan; Carla M Conroy; Mary Beth Serrano; Stephen J Ganocy; Joseph R Calabrese
Journal:  J Psychiatr Res       Date:  2014-09-19       Impact factor: 4.791

Review 6.  The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis.

Authors:  Tamara Pringsheim; Katie Wiltshire; Lundy Day; Jonathan Dykeman; Thomas Steeves; Nathalie Jette
Journal:  Mov Disord       Date:  2012-06-12       Impact factor: 10.338

7.  Suicide risk in Huntington's disease.

Authors:  L Di Maio; F Squitieri; G Napolitano; G Campanella; J A Trofatter; P M Conneally
Journal:  J Med Genet       Date:  1993-04       Impact factor: 6.318

Review 8.  Suicide risk associated with drug and alcohol dependence.

Authors:  N S Miller; J C Mahler; M S Gold
Journal:  J Addict Dis       Date:  1991

9.  Suicide among Hispanics--United States, 1997-2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-06-11       Impact factor: 17.586

Review 10.  Perceived barriers and facilitators to mental health help-seeking in young people: a systematic review.

Authors:  Amelia Gulliver; Kathleen M Griffiths; Helen Christensen
Journal:  BMC Psychiatry       Date:  2010-12-30       Impact factor: 3.630

View more
  2 in total

1.  Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.

Authors:  Noelle E Carlozzi; Siera Goodnight; Anna L Kratz; Julie C Stout; Michael K McCormack; Jane S Paulsen; Nicholas R Boileau; David Cella; Rebecca E Ready
Journal:  J Huntingtons Dis       Date:  2019

2.  International Guidelines for the Treatment of Huntington's Disease.

Authors:  Anne-Catherine Bachoud-Lévi; Joaquim Ferreira; Renaud Massart; Katia Youssov; Anne Rosser; Monica Busse; David Craufurd; Ralf Reilmann; Giuseppe De Michele; Daniela Rae; Ferdinando Squitieri; Klaus Seppi; Charles Perrine; Clarisse Scherer-Gagou; Olivier Audrey; Christophe Verny; Jean-Marc Burgunder
Journal:  Front Neurol       Date:  2019-07-03       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.